📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
33 announcements match the current filters (relevance ≥ 5).
Mankind Pharma Reaffirmed [ICRA]AA+ (Stable) Rating for ₹5,000 Crore NCDs
ICRA Limited has reaffirmed the credit ratings for Mankind Pharma Limited, maintaining a high-grade [ICRA]AA+ (Stable) for its ₹5,000 crore Non-convertible Debentures. The rating agency also reaffirmed the [ICRA]AA+ (Stable) and [ICRA]A1+ ratings for ₹1,250 crore in fund-based limits. Furthermore, a new [ICRA]A1+ rating was assigned to the company's ₹600 crore Commercial Paper program. These ratings reflect the company's robust financial profile and strong creditworthiness in the pharmaceutical sector.
Key Highlights
ICRA reaffirmed [ICRA]AA+ (Stable) rating for ₹5,000 crore Non-convertible Debentures
Reaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ for ₹1,250 crore fund-based limits
Assigned a new [ICRA]A1+ rating for ₹600 crore Commercial Paper
Total rated debt instruments and limits amount to ₹6,850 crore
👀 What to Watch
Investors should take confidence in the company's high credit rating, which indicates a strong ability to meet financial obligations and access capital at competitive rates. No immediate action is required as the ratings remain stable.
Mankind Pharma Assigned CARE AA+; Stable Rating for ₹1,000 Crore Bank Facilities
Mankind Pharma Limited has received new credit ratings from CARE Ratings Limited for its bank facilities totaling ₹1,000 crore. The agency assigned a 'CARE AA+; Stable' rating for long-term facilities and 'CARE A1+' for short-term facilities. These high investment-grade ratings underscore the company's robust credit profile and strong liquidity position. Such ratings typically allow the company to access capital at competitive interest rates and reflect a low risk of default.
Key Highlights
CARE Ratings assigned 'CARE AA+; Stable' for long-term bank facilities.
Short-term bank facilities were assigned the highest possible rating of 'CARE A1+'.
The total value of the bank facilities covered under this rating assignment is ₹1,000 crore.
The ratings were assigned at the request of the company to assess its creditworthiness.
👀 What to Watch
The high credit rating confirms Mankind Pharma's financial stability and strong balance sheet. Investors should view this as a positive indicator of the company's ability to manage debt and fund future growth at optimal costs.
Mankind Pharma Acquires Roche's Rivotril Brand to Strengthen CNS Portfolio in India
Mankind Pharma has acquired the exclusive rights to manufacture, market, and distribute the innovator brand Rivotril (clonazepam) from Roche for the Indian market. This acquisition is a strategic move to bolster Mankind's presence in the Central Nervous System (CNS) and chronic therapy segments, which are high-growth areas. The company plans to leverage its massive distribution network of over 17,700 professionals and reach of 5 lakh doctors to scale the brand. This deal follows Mankind's recent focus on specialty segments and high-margin chronic therapies to diversify its portfolio.
Key Highlights
Acquired exclusive rights for the innovator brand Rivotril from Roche for the Indian market
Strengthens strategic focus on chronic therapies and the Central Nervous System (CNS) segment
Leverages a distribution network of 17,700+ professionals and 32 manufacturing facilities
Aims to utilize a reach of over 5 lakh doctors to drive penetration in urban and semi-urban markets
Creates a platform for future expansion through potential line extensions in the CNS category
👀 What to Watch
Investors should view this as a positive development as it enhances Mankind's portfolio with a high-recall innovator brand in the chronic segment. Monitor the company's execution in scaling this brand and its impact on overall margins in the coming quarters.
Mankind Pharma Credit Ratings Reaffirmed by ICRA for ₹6,250 Crore Debt Instruments
ICRA Limited has reaffirmed the credit ratings for Mankind Pharma's debt instruments totaling ₹6,250 crore. The Non-Convertible Debentures (NCDs) worth ₹5,000 crore maintained an [ICRA]AA+/Stable rating. Additionally, long-term and short-term fund-based limits of ₹1,250 crore were reaffirmed at [ICRA]AA+ (Stable) and [ICRA]A1+ respectively. This reaffirmation reflects the company's strong financial profile and continued creditworthiness in the pharmaceutical sector.
Key Highlights
ICRA reaffirmed [ICRA]AA+/Stable rating for ₹5,000 crore Non-Convertible Debentures.
Fund-based limits of ₹1,250 crore reaffirmed at [ICRA]AA+ (Stable) and [ICRA]A1+.
Total debt instruments covered under this rating action amount to ₹6,250 crore.
The 'Stable' outlook indicates ICRA's expectation of consistent performance and credit metrics.
👀 What to Watch
The reaffirmation of high credit ratings confirms the company's strong balance sheet and low default risk. Investors should view this as a validation of financial stability, requiring no immediate portfolio changes.
Mankind Pharma Subsidiary BSV Subjected to 6-Day GST Search and Inspection
The GST Department, Mumbai, conducted a search and inspection operation at Bharat Serums and Vaccines Limited (BSV), a wholly owned subsidiary of Mankind Pharma. The operation took place over six days, from February 3 to February 8, 2026, under Section 67 of the Maharashtra GST Act. The inspection focused on tax payments, input tax credit claims, reconciliation, and refunds. Mankind Pharma has officially stated that the search has resulted in no material impact on the subsidiary's financials or operations.
Key Highlights
Search conducted by Assistant Commissioner of State Tax (Investigation – B), Mumbai
Operation lasted 6 days from February 3 to February 8, 2026
Focus areas included GST tax payments, input tax credit (ITC) reconciliation, and refunds
Management confirms no material impact on BSV's financial or operational activities
BSV is a wholly owned unlisted subsidiary of Mankind Pharma Limited
👀 What to Watch
Investors should monitor for any subsequent tax demand notices or penalties that may arise from this inspection. While the company claims no material impact, any future liability could affect the subsidiary's valuation.
Mankind Pharma Q3 FY26 Revenue Up 11.5% to ₹3,567 Cr; Adjusted EBITDA Margin at 25.9%
Mankind Pharma reported a steady Q3 FY26 with revenue growing 11.5% YoY to INR 3,567 crores, driven by an 11.1% increase in domestic sales and 14% growth in exports. The company's adjusted EBITDA margin stood at 25.9%, while the chronic segment's contribution rose to 36.7% of total sales. Integration of the BSV acquisition showed positive results with double-digit growth, and the company successfully reduced its net debt to INR 4,294 crores. Management highlighted a recovery in volume growth and significant outperformance in cardio and anti-diabetic therapies compared to the market.
Key Highlights
Q3 FY26 revenue increased 11.5% YoY to ₹3,567 crores with an adjusted EBITDA margin of 25.9%.
Chronic therapy contribution rose to 36.7%, with cardio and anti-diabetes growing at 16.7% and 14.4% respectively.
Export revenue for 9M FY26 surged 51% YoY to ₹1,503 crores, supported by EU GMP certification for the Udaipur facility.
Net debt reduced to ₹4,294 crores, bringing the net debt to adjusted EBITDA ratio down to 1.3x.
Domestic PCPM improved to ₹7.2 lakhs from ₹6.5 lakhs on a trailing 12-month basis.
👀 What to Watch
Investors should monitor the continued integration of BSV and the recovery in the acute segment. The stock remains a strong play on the domestic chronic market and expanding export capabilities.
Mankind Pharma Q3 FY26 Standalone PAT at ₹449.47 Cr; Revenue at ₹2,632.68 Cr
Mankind Pharma reported a steady performance for Q3 FY26 with standalone revenue from operations at ₹2,632.68 crore, showing a marginal sequential dip from ₹2,636.95 crore in Q2. Standalone Profit After Tax (PAT) stood at ₹449.47 crore, slightly lower than the ₹462.27 crore reported in the previous quarter, partly due to an exceptional item of ₹83.42 crore. The financial results have been restated to account for the acquisition of Bharat Serums and Vaccines Limited (BSV) and other business combinations. Overall, the company maintains a strong balance sheet with a total comprehensive income of ₹452.53 crore for the quarter.
Key Highlights
Standalone Revenue from operations stood at ₹2,632.68 crore for the quarter ended December 31, 2025.
Standalone Profit After Tax (PAT) reached ₹449.47 crore, impacted by an exceptional charge of ₹83.42 crore.
Basic Earnings Per Share (EPS) for the quarter was reported at ₹10.89.
Financials were restated to reflect the impact of the Bharat Serums and Vaccines Limited (BSV) acquisition.
Total expenses for the quarter were managed at ₹2,100.49 crore compared to ₹2,189.09 crore in the preceding quarter.
👀 What to Watch
Investors should monitor the integration progress of the BSV acquisition and the reasons behind the exceptional item. While sequential growth was flat, the company's domestic market leadership remains a key long-term positive.
Mankind Pharma Q3 FY26: Revenue up 11.5% to ₹3,567 Cr; Chronic share rises to 39.3%
Mankind Pharma reported a steady 11.5% YoY revenue growth in Q3 FY26, reaching ₹3,567 crore, primarily driven by domestic pharma and the consolidation of BSV. The company's chronic segment showed strong momentum, with its share increasing by 200bps to 39.3%, led by high growth in Cardiac (16.7%) and Anti-Diabetes (14.4%) therapies. While reported EBITDA margins were 22.9%, adjusted margins stood at 25.9% after accounting for one-time labor code impacts. The Consumer Healthcare segment regained momentum with 5.2% growth, and the export business grew by 14.1% YoY.
Key Highlights
Revenue from operations grew 11.5% YoY to ₹3,567 crore, with domestic business contributing ₹3,046 crore.
Chronic segment share increased to 39.3% from 37.3% YoY, significantly outperforming the Indian Pharma Market (IPM) in key therapies.
Adjusted EBITDA margin stood at 25.9%, while PAT grew 9.5% YoY to ₹414 crore.
Export business witnessed 14.1% YoY growth, reaching ₹521 crore, aided by BSV international business.
Net debt reduced to ₹4,294 crore as of Dec 31, 2025, from ₹6,739 crore in Dec 2024, showing strong cash flow utilization.
👀 What to Watch
Investors should focus on the company's successful transition toward a higher-margin chronic portfolio and the smooth integration of the BSV acquisition. The stock remains a strong play on the domestic pharmaceutical market with improving capital efficiency.
Mankind Pharma Q3 Revenue Up 11.5% to ₹3,567 Cr; Adj. EBITDA Margin at 25.9%
Mankind Pharma reported a steady 11.5% YoY revenue growth in Q3 FY26, reaching ₹3,567 crore, primarily driven by domestic pharma and the consolidation of BSV. The company's chronic segment share improved by 200bps to 39.3%, with strong performance in cardiac (16.7%) and anti-diabetes (14.4%) therapies. While reported EBITDA margins saw compression to 22.9% due to one-time costs, the adjusted EBITDA margin remained healthy at 25.9%. Consumer healthcare showed signs of recovery with 5.2% growth compared to a decline in the previous quarter.
Key Highlights
Revenue from operations grew 11.5% YoY to ₹3,567 Cr, with domestic revenue up 11.1% to ₹3,046 Cr.
Chronic therapy share increased to 39.3% of total revenue, led by 16.7% growth in Cardiac and 14.4% in Anti-Diabetics.
Adjusted EBITDA margin stood at 25.9% after adjusting for one-time labor code impacts and non-recurring costs.
Consumer Healthcare (OTC) returned to growth at 5.2% YoY, a significant recovery from the -2.6% growth in Q2 FY26.
Export revenue increased 14.1% YoY to ₹521 Cr, supported by the BSV international business.
👀 What to Watch
Investors should focus on the company's successful shift towards high-margin chronic therapies and the recovery in the OTC segment. The integration of BSV appears to be progressing well, providing a strong foundation for long-term sustainable growth.
Mankind Pharma Q3 FY26 Standalone PAT at ₹449.47 Cr; Revenue at ₹2,632.68 Cr
Mankind Pharma reported a standalone revenue of ₹2,632.68 crore for the quarter ended December 31, 2025, remaining largely flat compared to ₹2,636.95 crore in the previous quarter. Net profit for the period stood at ₹449.47 crore, a slight sequential decline from ₹462.27 crore, partly due to an exceptional item of ₹83.42 crore. The financials have been restated to incorporate the acquisition of Bharat Serums and Vaccines Limited (BSV). The company also noted ongoing income tax litigation which is currently under appeal.
Key Highlights
Standalone Revenue from operations recorded at ₹2,632.68 crore for Q3 FY26
Profit After Tax (PAT) reached ₹449.47 crore, down 2.7% sequentially
An exceptional item of ₹83.42 crore impacted the quarterly bottom line
Financial results restated to reflect the business combination with Bharat Serums and Vaccines Limited (BSV)
Basic EPS for the quarter stood at ₹10.89 compared to ₹11.20 in the preceding quarter
👀 What to Watch
Investors should focus on the consolidated performance to gauge the full impact of the BSV acquisition and monitor the resolution of pending tax proceedings. The slight sequential dip in standalone margins warrants a cautious watch on operational costs.
Mankind Pharma Maintains AA+ Rating; Withdraws ₹1,500 Cr Commercial Paper Rating
Mankind Pharma has announced the withdrawal of its (ICRA) A1+ credit rating for Commercial Paper worth ₹1,500 crore at its own request. Despite this withdrawal, the company's core credit profile remains strong with an outstanding (ICRA) AA+/Stable rating for its ₹5,000 crore Non-Convertible Debentures. Additionally, fund-based limits totaling ₹1,250 crore retain their high-grade (ICRA) AA+ (Stable) and (ICRA) A1+ ratings. This update confirms that the company's creditworthiness and ability to service debt remain robust.
Key Highlights
ICRA withdrew the (ICRA) A1+ rating for ₹1,500 crore Commercial Paper at the company's request.
Outstanding rating for ₹5,000 crore Non-Convertible Debentures remains stable at (ICRA) AA+.
Long-term and short-term fund-based limits of ₹1,250 crore maintain (ICRA) AA+ (Stable) and (ICRA) A1+ ratings.
The withdrawal of the CP rating is a procedural action and does not indicate a downgrade in credit quality.
👀 What to Watch
Investors should treat this as a routine administrative update as the company's primary credit ratings remain high and stable. No immediate action is required as the fundamental debt-servicing capability remains unchanged.
Mankind Pharma Assigned ESG Rating of 71 by NSE Sustainability
Mankind Pharma Limited has been assigned an Environmental, Social, and Governance (ESG) rating of 71 for FY25 by NSE Sustainability Ratings and Analytics Limited. This rating was assigned independently based on publicly available information, as the company did not specifically engage the provider for this service. The disclosure is in compliance with SEBI's Master Circular for ESG Rating Providers. A score of 71 suggests a robust framework in sustainability and governance, which is a key metric for institutional and foreign investors.
Key Highlights
NSE Sustainability assigned an ESG rating of 71 to Mankind Pharma for the 2025 financial year.
The rating was assigned independently using publicly available information without company engagement.
The disclosure follows the SEBI Master Circular dated November 11, 2024, regarding ESG Rating Providers.
👀 What to Watch
Monitor how this rating compares to industry peers to gauge the company's relative sustainability standing. This positive score may enhance the stock's attractiveness to ESG-mandated institutional funds.
Mankind Pharma Assigned ESG Rating of 71 by NSE Sustainability for FY25
Mankind Pharma has been assigned an Environmental, Social, and Governance (ESG) rating of 71 by NSE Sustainability Ratings and Analytics Limited for the financial year 2025. This rating was assigned independently by the SEBI-registered provider based on publicly available information, without direct engagement from the company. The disclosure follows the SEBI Master Circular dated November 11, 2024, regarding ESG rating providers. Such ratings are increasingly critical for institutional investors and ESG-focused funds when evaluating non-financial risk and sustainability.
Key Highlights
NSE Sustainability assigned an ESG rating of 71 to Mankind Pharma for FY25.
The rating was conducted independently based on publicly available data without company engagement.
Disclosure is compliant with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155.
The rating provides a benchmark for the company's environmental, social, and governance performance.
👀 What to Watch
Investors should note this rating as it enhances the company's profile for ESG-mandated institutional funds. No immediate portfolio changes are necessary, but the score should be compared against pharmaceutical industry peers.
